Menu

Lipitor Patent Expires

The pharmaceutical darling that has brought billions in revenue to Pfizer over the past 15 years will now share the shelves with its generic competitors.

Nov 30, 2011
Cristina Luiggi

DREAMSTIME, KATERYNA PORTOKHOVA

Pfizer’s monopoly over the blockbuster cholesterol-reducing molecule atorvastatin, trade name Lipitor, ends today (November 30) with the expiration of the patent that has brought the company over $100 billion since the drug was introduced in 1997. While the introduction of generic alternatives into the market may pose a relief for consumer pockets, the expiration of patents for Lipitor and other drugs in the next three years may result in a loss of about $95 billion for big drug companies, Nature reported.

Atorvastatin was first synthesized in 1985 by Bruce D. Roth, a chemist working at Parke-Davis Warner-Lambert Company (now Pfizer). Modeled after naturally occurring compounds known as statins, atorvastatin reduces blood cholesterol by inhibiting a key liver enzyme involved in the production of cholesterol. When Lipitor splashed into the market in 1997, it was celebrated as a marked improvement over available drugs due to its high efficiency and few side effects.

But the past decade has not boded well for pharmaceutical companies, as investors have come to realize that success stories such as Lipitor’s are more the exception than the norm. As a result, big companies such as Pfizer have drastically reduced their research and development budgets, and many are shying away from possible blockbusters and turning toward more niche drugs, according to Nature.

Generic Lipitor, produced by New Jersey-based Watson Pharmaceuticals Inc., will be available as early as December 5, with other companies following suit pending FDA clearance, Bloomberg reported.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!